The consultation is now open - your support could influence the outcome!
The deadline for comments is 4th December 2017 - 5.00pm
The Department of Health has asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using teduglutide in the NHS in England. The appraisal committee has considered the evidence submitted by the company and the views of non-company consultees and commentators, clinical experts and patient experts.
We, PINNT, were able to use our Short Bowel Syndrome Survey (SBS) resutls to represent life with SBS/IF/HPN.
It's now time for you to comments on the outcome of the appraisal.
The appraisal committee is interested in receiving comments on the following:
· Has all of the relevant evidence been taken into account?
· Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
· Are the recommendations sound and a suitable basis for guidance to the NHS?
· Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
You can comment on this appraisal - to do this use this link: https://www.nice.org.uk/guidance/indevelopment/gid-ta10048/consultation/html-content
You will then need to log in if you have an account or set one up before being able to comment.
You must read the Appraisal Consultation Document https://www.nice.org.uk/guidance/GID-TA10048/documents/appraisal-consultation-document having done so you can then submit your comments.